Cargando…
Comparison of the use of screening tools for evaluating cognitive impairment in patients with Parkinson's disease
BACKGROUND: Screening tests have been used for cognitive deficits in Parkinson's disease (PD). OBJECTIVE: This study compared the Montreal Cognitive Assessment (MoCA) test, the Mini-Mental State Examination (MMSE) and the clock drawing test for this purpose. METHODS: A total of 50 patients with...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Associação de Neurologia Cognitiva e do
Comportamento
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5619276/ https://www.ncbi.nlm.nih.gov/pubmed/29213480 http://dx.doi.org/10.1590/s1980-5764-2016dn1004015 |
_version_ | 1783267366307627008 |
---|---|
author | Camargo, Carlos Henrique Ferreira Tolentino, Eduardo de Souza Bronzini, Augusto Ladeira, Marcelo de Araújo Lima, Ronilson Schultz-Pereira, Gustavo Leopold Young-Blood, Marcelo Rezende |
author_facet | Camargo, Carlos Henrique Ferreira Tolentino, Eduardo de Souza Bronzini, Augusto Ladeira, Marcelo de Araújo Lima, Ronilson Schultz-Pereira, Gustavo Leopold Young-Blood, Marcelo Rezende |
author_sort | Camargo, Carlos Henrique Ferreira |
collection | PubMed |
description | BACKGROUND: Screening tests have been used for cognitive deficits in Parkinson's disease (PD). OBJECTIVE: This study compared the Montreal Cognitive Assessment (MoCA) test, the Mini-Mental State Examination (MMSE) and the clock drawing test for this purpose. METHODS: A total of 50 patients with PD were selected, 41 (82%) were diagnosed with dementia by the criteria of the Movement Disorder Society. The test Scales for Outcomes in Parkinson's Disease-Cognition (SCOPA-Cog) was used as the gold standard in comparison with the screening tests. RESULTS: The MoCA test (AUC=0.906) had a sensitivity of 87.80% and specificity of 88.89%. When the MMSE was associated with the clock drawing test (AUC=0.936), it had a specificity of 66.67% and sensitivity of up to 97.56%. CONCLUSION: The study suggests that the MoCA test can be a good screening test in PD. However, MMSE associated with the clock drawing test may be more effective than the MoCA test. |
format | Online Article Text |
id | pubmed-5619276 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Associação de Neurologia Cognitiva e do
Comportamento |
record_format | MEDLINE/PubMed |
spelling | pubmed-56192762017-12-06 Comparison of the use of screening tools for evaluating cognitive impairment in patients with Parkinson's disease Camargo, Carlos Henrique Ferreira Tolentino, Eduardo de Souza Bronzini, Augusto Ladeira, Marcelo de Araújo Lima, Ronilson Schultz-Pereira, Gustavo Leopold Young-Blood, Marcelo Rezende Dement Neuropsychol Original Articles BACKGROUND: Screening tests have been used for cognitive deficits in Parkinson's disease (PD). OBJECTIVE: This study compared the Montreal Cognitive Assessment (MoCA) test, the Mini-Mental State Examination (MMSE) and the clock drawing test for this purpose. METHODS: A total of 50 patients with PD were selected, 41 (82%) were diagnosed with dementia by the criteria of the Movement Disorder Society. The test Scales for Outcomes in Parkinson's Disease-Cognition (SCOPA-Cog) was used as the gold standard in comparison with the screening tests. RESULTS: The MoCA test (AUC=0.906) had a sensitivity of 87.80% and specificity of 88.89%. When the MMSE was associated with the clock drawing test (AUC=0.936), it had a specificity of 66.67% and sensitivity of up to 97.56%. CONCLUSION: The study suggests that the MoCA test can be a good screening test in PD. However, MMSE associated with the clock drawing test may be more effective than the MoCA test. Associação de Neurologia Cognitiva e do Comportamento 2016 /pmc/articles/PMC5619276/ /pubmed/29213480 http://dx.doi.org/10.1590/s1980-5764-2016dn1004015 Text en http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Articles Camargo, Carlos Henrique Ferreira Tolentino, Eduardo de Souza Bronzini, Augusto Ladeira, Marcelo de Araújo Lima, Ronilson Schultz-Pereira, Gustavo Leopold Young-Blood, Marcelo Rezende Comparison of the use of screening tools for evaluating cognitive impairment in patients with Parkinson's disease |
title | Comparison of the use of screening tools for evaluating cognitive
impairment in patients with Parkinson's disease |
title_full | Comparison of the use of screening tools for evaluating cognitive
impairment in patients with Parkinson's disease |
title_fullStr | Comparison of the use of screening tools for evaluating cognitive
impairment in patients with Parkinson's disease |
title_full_unstemmed | Comparison of the use of screening tools for evaluating cognitive
impairment in patients with Parkinson's disease |
title_short | Comparison of the use of screening tools for evaluating cognitive
impairment in patients with Parkinson's disease |
title_sort | comparison of the use of screening tools for evaluating cognitive
impairment in patients with parkinson's disease |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5619276/ https://www.ncbi.nlm.nih.gov/pubmed/29213480 http://dx.doi.org/10.1590/s1980-5764-2016dn1004015 |
work_keys_str_mv | AT camargocarloshenriqueferreira comparisonoftheuseofscreeningtoolsforevaluatingcognitiveimpairmentinpatientswithparkinsonsdisease AT tolentinoeduardodesouza comparisonoftheuseofscreeningtoolsforevaluatingcognitiveimpairmentinpatientswithparkinsonsdisease AT bronziniaugusto comparisonoftheuseofscreeningtoolsforevaluatingcognitiveimpairmentinpatientswithparkinsonsdisease AT ladeiramarcelodearaujo comparisonoftheuseofscreeningtoolsforevaluatingcognitiveimpairmentinpatientswithparkinsonsdisease AT limaronilson comparisonoftheuseofscreeningtoolsforevaluatingcognitiveimpairmentinpatientswithparkinsonsdisease AT schultzpereiragustavoleopold comparisonoftheuseofscreeningtoolsforevaluatingcognitiveimpairmentinpatientswithparkinsonsdisease AT youngbloodmarcelorezende comparisonoftheuseofscreeningtoolsforevaluatingcognitiveimpairmentinpatientswithparkinsonsdisease |